Elizabeth A. Holmberg
Vice President, Finance and Corporate Development
Elizabeth A. Holmberg oversees the planning and execution of strategies to meet financial and organizational objectives for Third Pole. Previously, Elizabeth served as Vice President of Finance at MannKind Corporation, a biopharmaceutical company whose lead product, Afrezza®, an inhaled prandial insulin, was approved in 2014, where she was responsible for financial operations and strategic partnering. Prior to MannKind, Elizabeth was the Chief Financial Officer for Ikaria after spending many years in finance and strategic planning roles of increasing responsibility with Ohmeda, Becton Dickinson and INO Therapeutics. INO Therapeutics was the first company to gain FDA approval for inhaled nitric oxide therapy, prior to being acquired by Ikaria. Elizabeth joined INO Therapeutics prior to the approval of INOmax® and had direct responsibility for the accounting, finance and planning functions for the company through their transition from a clinical start-up to a fully integrated, commercial pharmaceutical company. Elizabeth received an MBA from New York University’s Leonard N. Stern School of Business and a Bachelor of Science in Accounting from The William Paterson University of New Jersey.